Tradestie Institutional Equity Comparison Engine · Market Close Nov 17, 2026

ATYR vs INMB: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

ATYR Captures Overall Composite Edge (34.3 SELL vs 41.5 SELL), While INMB Leads 3–1 on Growth & Valuation Pillars

ATYR Overall Winner 6-Pillar Tally: ATYR 1 – 3 INMB (2 Tie) Matrix Metrics: ATYR 1 – 5 INMB

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over INmune Bio Inc. (INMB) on higher Unified Composite conviction (34.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 1–5 (led by Options & Positioning), while INMB wins 3–1 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus INMB at $0.98 (N/M Forward P/E, 0.0% operating margin).

  • Composite vs. Pillar Nuance: While INMB currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +257.1% YoY).
  • Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ATYR (34.3/100 SELL) and INMB (41.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model.
  • Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.9); meanwhile INMB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About ATYR vs INMB
ATYR NASDAQ Head-to-Head Winner
aTyr Pharma, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$4.96
-5.34% 1D
Market Cap $15.6M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol -9.67β · 13806% Vol
Unified Composite Score
34.3 / 100 SELL
Tech 50.0 Fund 36.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (391.6% over 20 days), RSI 58
RSI-14: 57.9 · SMA20: $4.36 · SMA50: $1.93
INMB NASDAQ
INmune Bio Inc. Common stock
Biological Products, (No Disgnostic Substances)
$0.98
+3.49% 1D
Market Cap $32.5M
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 2.64β · 74% Vol
Unified Composite Score
41.5 / 100 SELL
Tech 25.0 Fund 50.0 Flow 69.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -18.7%), weak momentum, RSI 19
RSI-14: 19.3 · SMA20: $1.29 · SMA50: $1.70

6-Pillar Scorecard Institutional Category Breakdown (ATYR 1 – 3 INMB)

Columns: Metric · ATYR · INMB
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale INMB
Revenue Growth (YoY) +0.0% +257.1%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) N/A N/A
Market Cap $15.6M $32.5M
3. Profitability & Quality INMB
Gross Margin N/A N/A
Operating Margin 0.0% 0.0%
Net Profit Margin 0.0% 0.0%
Return on Equity (ROE) -93.7% -76.7%
4. Balance Sheet & Cash Flow INMB
Cash Generation (TTM) N/A -$13M
Cash Flow Margin N/A N/A
Net Cash / Leverage $4.9M Net Cash $15M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning ATYR
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile 154.5% (36th %ile) 326.9% (45th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Markup DISTRIBUTION · Markdown
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: ATYR (1) vs INMB (5)
Institutional Metric ATYR INMB Criterion Row Edge
Market Capitalization
Scale
$15.6M $32.5M Larger Scale INMB
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+0.0% +257.1% Higher Growth INMB
Operating Margin (TTM)
Profitability
0.0% 0.0% Higher Margin Tie
Net Profit Margin
Profitability
0.0% 0.0% Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
-93.7% -76.7% Higher ROE INMB
52-Week Range Position
Momentum
62% ($0–$8) 5% ($1–$3) Stronger Trend ATYR
Beta / 30D Volatility
Risk Regime
-9.67β · 13806% Vol 2.64β · 74% Vol Lower Realized Risk INMB
Unified Institutional Score
Composite Signal
34.3 / 100 (SELL) 41.5 / 100 (SELL) Higher Composite INMB
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A ($4.9M Net Cash) -$13M ($15M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ATYR +2825.16 pp
ATYR: +2788.76% · INMB: -36.4%
3M Horizon ATYR +887.01 pp
ATYR: +830.93% · INMB: -56.08%
6M Horizon ATYR +957.46 pp
ATYR: +926.92% · INMB: -30.54%
1Y Horizon ATYR +589.73 pp
ATYR: +558.7% · INMB: -31.03%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period ATYR Revenue INMB Revenue ATYR Op. Margin INMB Op. Margin Margin Leader
FY2019 $0M N/A -5445.0% N/A ATYR
FY2020 $10M $0M -152.2% -111163.6% ATYR
FY2021 N/A $0M N/A -16106.6% INMB
FY2022 $10M $0M -446.8% -6938.8% ATYR
FY2023 $0M $0M -15557.8% -19187.7% ATYR
FY2024 $0M $0M -28899.6% -304535.7% ATYR
FY2025 $0M $0M -40856.3% -94766.0% ATYR

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
ATYR UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 154.5%
IV Percentile 36th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact ATYR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
INMB BREAKDOWN
50d in phase · OBV DISTRIBUTION
Current IV 326.9%
IV Percentile 45th %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact INMB Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
ATYR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $15.6M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
INMB Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $32.5M market capitalization and 0.0% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ ATYR vs INMB Key Questions & Quantitative Answers

As of Nov 17, 2026, aTyr Pharma, Inc. (ATYR) captures the overall head-to-head institutional edge over INmune Bio Inc. (INMB) on higher Unified Composite conviction (34.3/100 SELL vs. 41.5/100 SELL) after splitting the core matrix 1–5 (led by Options & Positioning), while INMB wins 3–1 across the 6-pillar growth and valuation breakdown. ATYR trades at $4.96 (N/M Forward P/E, 0.0% operating margin) versus INMB at $0.98 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While INMB currently prints a higher short-term Unified Composite Score (41.5/100 SELL vs. ATYR 34.3/100 SELL), ATYR captures the overall institutional head-to-head verdict (1–5 matrix metrics and 1–3 across the 6 pillars) due to superior fundamental profitability (0.0% vs. 0.0% operating margin) and revenue trajectory (+0.0% vs. +257.1% YoY). Defensive Composite Rating Caution: Although ATYR compares more favorably head-to-head, both ATYR (34.3/100 SELL) and INMB (41.5/100 SELL) currently screen in defensive SELL territory (<42/100) on our Unified Composite model. Technical & Structure Timing Caution: ATYR trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 57.9); meanwhile INMB is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 19.3). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

INMB leads the Growth & Scale pillar: ATYR posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with INMB at +257.1% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), ATYR cumulative revenue shifted +0.0% while INMB shifted N/A. In operating R&D and SG&A reinvestment, ATYR deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for INMB.

ATYR and INMB trade at balanced relative valuation multiples. ATYR trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas INMB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against ATYR (-93.7% ROE) versus INMB (-76.7% ROE) capital efficiency.

In options market volatility and institutional positioning, ATYR carries 154.5% implied volatility (36th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-9.67β · 13806% Vol realized risk). By comparison, INMB carries 326.9% implied volatility (45th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.64β · 74% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 17, 2026. For educational research only; not investment advice.